Sanofi has joined hands with Atomwise to utilise the former’s AI-sponsored platform to further research. With the help of AtomNet, Atomwise’s AI technology, the firms intend to discover up to five drugs. This innovative technology enables efficient and structure-based discovery of drugs that the traditional methods do not offer. The purpose of this multi-million dollar collaboration is to produce medicines that the traditional research approach fails to offer. Therefore, by making the best use of the technology at hand, the two firms can accelerate drug discovery for conditions that could go unrecognised and untreated without the AI-driven technologies, says the CEO of Atomwise, Abraham Heifets.
Read More from Pharmaceutical Technology